These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 29175269)

  • 1. Sclerostin deficiency modifies the development of CKD-MBD in mice.
    Kaesler N; Verhulst A; De Maré A; Deck A; Behets GJ; Hyusein A; Evenepoel P; Floege J; Marx N; Babler A; Kramer I; Kneissel M; Kramann R; Weis D; D'Haese PC; Brandenburg VM
    Bone; 2018 Feb; 107():115-123. PubMed ID: 29175269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Only minor differences in renal osteodystrophy features between wild-type and sclerostin knockout mice with chronic kidney disease.
    Cejka D; Parada-Rodriguez D; Pichler S; Marculescu R; Kramer I; Kneissel M; Gross T; Reisinger A; Pahr D; Monier-Faugere MC; Haas M; Malluche HH
    Kidney Int; 2016 Oct; 90(4):828-34. PubMed ID: 27528549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength.
    Li X; Ominsky MS; Niu QT; Sun N; Daugherty B; D'Agostin D; Kurahara C; Gao Y; Cao J; Gong J; Asuncion F; Barrero M; Warmington K; Dwyer D; Stolina M; Morony S; Sarosi I; Kostenuik PJ; Lacey DL; Simonet WS; Ke HZ; Paszty C
    J Bone Miner Res; 2008 Jun; 23(6):860-9. PubMed ID: 18269310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats.
    Meng Y; Zhang H; Li Y; Li Q; Zuo L
    Bone; 2014 Jan; 58():168-76. PubMed ID: 24145307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repression of osteocyte Wnt/β-catenin signaling is an early event in the progression of renal osteodystrophy.
    Sabbagh Y; Graciolli FG; O'Brien S; Tang W; dos Reis LM; Ryan S; Phillips L; Boulanger J; Song W; Bracken C; Liu S; Ledbetter S; Dechow P; Canziani ME; Carvalho AB; Jorgetti V; Moyses RM; Schiavi SC
    J Bone Miner Res; 2012 Aug; 27(8):1757-72. PubMed ID: 22492547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic kidney disease bone and mineral disorder (CKD-MBD) in apolipoprotein E-deficient mice with chronic renal failure.
    Nikolov IG; Joki N; Nguyen-Khoa T; Ivanovski O; Phan O; Lacour B; Drüeke TB; Massy ZA; Dos Reis LM; Jorgetti V; Lafage-Proust MH
    Bone; 2010 Jul; 47(1):156-63. PubMed ID: 20406703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mice with sclerostin gene deletion are resistant to the severe sublesional bone loss induced by spinal cord injury.
    Qin W; Zhao W; Li X; Peng Y; Harlow LM; Li J; Qin Y; Pan J; Wu Y; Ran L; Ke HZ; Cardozo CP; Bauman WA
    Osteoporos Int; 2016 Dec; 27(12):3627-3636. PubMed ID: 27436301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inactivation of Osteoblast PKC Signaling Reduces Cortical Bone Mass and Density and Aggravates Renal Osteodystrophy in Mice with Chronic Kidney Disease on High Phosphate Diet.
    Zaloszyc A; Choquet P; Sayeh A; Bartosova M; Schaefer B; Huegel U; Aubertin-Kirch G; Healy C; Severac F; Rizzo S; Boivin G; Schaefer F; Fischbach M; Bacchetta J; Bahram S; Schmitt CP
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From skeletal to cardiovascular disease in 12 steps-the evolution of sclerostin as a major player in CKD-MBD.
    Brandenburg VM; D'Haese P; Deck A; Mekahli D; Meijers B; Neven E; Evenepoel P
    Pediatr Nephrol; 2016 Feb; 31(2):195-206. PubMed ID: 25735207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sclerostin Protects Against Vascular Calcification Development in Mice.
    De Maré A; Opdebeeck B; Neven E; D'Haese PC; Verhulst A
    J Bone Miner Res; 2022 Apr; 37(4):687-699. PubMed ID: 35038187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conditional Deletion of Sost in MSC-Derived Lineages Identifies Specific Cell-Type Contributions to Bone Mass and B-Cell Development.
    Yee CS; Manilay JO; Chang JC; Hum NR; Murugesh DK; Bajwa J; Mendez ME; Economides AE; Horan DJ; Robling AG; Loots GG
    J Bone Miner Res; 2018 Oct; 33(10):1748-1759. PubMed ID: 29750826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Micro-CT in the Assessment of Pediatric Renal Osteodystrophy by Bone Histomorphometry.
    Pereira RC; Bischoff DS; Yamaguchi D; Salusky IB; Wesseling-Perry K
    Clin J Am Soc Nephrol; 2016 Mar; 11(3):481-7. PubMed ID: 26712809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sclerostin deficiency effectively promotes bone morphogenetic protein-2-induced ectopic bone formation.
    Nakamura K; Koide M; Kobayashi Y; Yamashita T; Matsushita M; Yasuda H; Ishihara Y; Yoshinari N; Udagawa N
    J Periodontal Res; 2023 Aug; 58(4):769-779. PubMed ID: 37154419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sclerostin Deficiency Promotes Reparative Dentinogenesis.
    Collignon AM; Amri N; Lesieur J; Sadoine J; Ribes S; Menashi S; Simon S; Berdal A; Rochefort GY; Chaussain C; Gaucher C
    J Dent Res; 2017 Jul; 96(7):815-821. PubMed ID: 28571484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased callus mass and enhanced strength during fracture healing in mice lacking the sclerostin gene.
    Li C; Ominsky MS; Tan HL; Barrero M; Niu QT; Asuncion FJ; Lee E; Liu M; Simonet WS; Paszty C; Ke HZ
    Bone; 2011 Dec; 49(6):1178-85. PubMed ID: 21890008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High phosphate feeding promotes mineral and bone abnormalities in mice with chronic kidney disease.
    Lau WL; Linnes M; Chu EY; Foster BL; Bartley BA; Somerman MJ; Giachelli CM
    Nephrol Dial Transplant; 2013 Jan; 28(1):62-9. PubMed ID: 23045434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sclerostin in chronic kidney disease-mineral bone disorder think first before you block it!
    Brandenburg VM; Verhulst A; Babler A; D'Haese PC; Evenepoel P; Kaesler N
    Nephrol Dial Transplant; 2019 Mar; 34(3):408-414. PubMed ID: 29846712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between aortic mineral elements and osteodystrophy in mice with chronic kidney disease.
    Matsumoto T; Fukushima S; Kanasaki T; Hagino S
    Biol Trace Elem Res; 2012 Dec; 150(1-3):278-84. PubMed ID: 22700181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium.
    Ryan ZC; Ketha H; McNulty MS; McGee-Lawrence M; Craig TA; Grande JP; Westendorf JJ; Singh RJ; Kumar R
    Proc Natl Acad Sci U S A; 2013 Apr; 110(15):6199-204. PubMed ID: 23530237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta.
    Roschger A; Roschger P; Keplingter P; Klaushofer K; Abdullah S; Kneissel M; Rauch F
    Bone; 2014 Sep; 66():182-8. PubMed ID: 24953712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.